The drucebo effect, a lesser-known counterpart to the nocebo effect, arises from negative perceptions specifically related to medical interventions and healthcare settings. This phenomenon can significantly influence the management of lymphedema, a chronic and often debilitating condition characterized by fluid retention and tissue swelling. The drucebo effect not only exacerbates symptom perception but also negatively impacts adherence to therapy and overall patient prognosis. This report explores the mechanisms underlying the drucebo effect in lymphedema management, the role of healthcare provider communication, and strategies to mitigate its impact. Addressing the drucebo effect is critical to optimizing therapeutic outcomes and enhancing patient satisfaction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/02683555251326698 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Breaking the cycle: Addressing the drucebo effect in lymphedema care.
Phlebology
March 2025
Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
The drucebo effect, a lesser-known counterpart to the nocebo effect, arises from negative perceptions specifically related to medical interventions and healthcare settings. This phenomenon can significantly influence the management of lymphedema, a chronic and often debilitating condition characterized by fluid retention and tissue swelling. The drucebo effect not only exacerbates symptom perception but also negatively impacts adherence to therapy and overall patient prognosis.
View Article and Find Full Text PDFBreaking the cycle: Addressing the drucebo effect in hand rehabilitation.
Hand Surg Rehabil
January 2025
Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. Electronic address:
Statin intolerance and the drucebo effect.
QJM
July 2024
St James's Hospital, Department of Pharmacology, St James's hospital, James's Street, Dublin 8, D08 NHY1, Ireland.
Hypercholesterolemia is a well-described risk factor for atherosclerotic cardiovascular disease (ASCVD). Statins remain the cornerstone of therapy. Statin intolerance (SI) particularly statin associated muscle symptoms (SAMS) and inappropriate stopping of treatment is associated with increased cardiovascular risk.
View Article and Find Full Text PDFPrescribing statin therapy in physically (in)active individuals vs prescribing physical activity in statin-treated patients: A four-scenario practical approach.
Pharmacol Res
November 2023
Department of Internal Medicine, Virgen de las Nieves University Hospital, Granada, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
Statins are among the most commonly prescribed medications worldwide. Statin-associated muscle symptoms (SAMS) represent a frequent statin-related adverse effect associated with statin discontinuation and increased cardiovascular disease (CVD) events. Emerging evidence indicate that the majority of SAMS might not be actually caused by statins, and the nocebo/drucebo effect (i.
View Article and Find Full Text PDFPatient-reported muscle symptoms and their characterization in a hypertensive population eligible for statin therapy: An exploratory study.
Nutr Metab Cardiovasc Dis
January 2024
Internal Medicine and Geriatrics, IRCCS INRCA, Ancona, Italy; Department of Clinical and Molecular Sciences, University "Politecnica delle Marche", Ancona, Italy.
Background And Aims: Statin-associated muscle symptoms (SAMS) are claimed to be frequent in clinical practice. We evaluated the prevalence and characteristics of patient-reported muscle symptoms (PRMS) attributed to drugs/nutraceuticals in hypertensive patients, focusing the attention on statin treatment.
Methods And Results: Observational study on 390 consecutive outpatients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!